

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SCOTT, *et al.*

Serial No.: To be assigned

Filed: 7 July 2006

For: DIABETOGENIC EPITOPES

Art Unit: To be assigned

Examiner: To be assigned

Atty. Dckt: 034205.003

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Listed on the accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. § 1.56, 1.97 and 1.98. Copies of the references are enclosed. Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.


This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

This Information Disclosure Statement is being filed within three months of the U.S. filing date or before the mailing date of a first Office Action on the merits. No certification or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our **Deposit Account No. 02-4300**, Attorney Docket No. **034205.003**.

Respectfully submitted,



Suzannah K. Sundby
Registration No. 43,172

Date: 7 July 2006

SMITH, GAMBRELL & RUSSELL, LLP

1850 M Street, N.W., Suite 800

Washington, D.C. 20036

Telephone: (202) 263-4332

Fax: (202) 263-4352

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 034205.003	SERIAL NO. Not yet assigned
		Scott et al.	
		FILING DATE 7 July 2006	GROUP ART UNIT To be assigned

U.S. PATENT DOCUMENTS

*Examiner's Initials		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE, IF APPROPRIATE
	AA	US 20040216190A1	28 Oct. 2004	Kovalic	800	289	18 Dec. 2003

FOREIGN PATENT DOCUMENTS

*Examiner's Initials		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	AB	WO 01/24793 A2	12 Apr. 2001	WIPO	G01N	33/68	X

OTHER INFORMATION (Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner's Initials		Author, et al. (DATE) "Title", Book/Journal, X(X):pp-pp.
	AC	Okita et al. (1985) "Evolution and Heterogeneity of the α - β -Type and γ -Type Gliadin DNA Sequences" J. Biol. Chem. 260(13):8203-8213.
	AD	Litts et al. (1993) "Genomic Nucleotide Sequence of Triticum Aestivum 7S Globulin (Gb11) Storage Protein Gene" GenBank accession number M81719.1
	AE	Osman et al. (2001) "A Monoclonal Antibody that Recognizes a Potential Coeliac-Toxic Repetitive Pentapeptide Epitope in Gliadins" European J of Gastroent. & Hepatol. 13(10):1189-1193.
	AF	Garcia et al. (2003) "Development of a Monoclonal Antibody Capable of Detecting Prolamine in Wheat and Oats" Hybridoma and Hybridomics 22(6):383-388.
	AG	MacFarlane et al. (2003) "A Type I Diabetes-Related Protein from Wheat (<i>Triticum aestivum</i>)" J. Biol. Chem. 278(1):54-63.

EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	